Experimental PARP inhibitor combo trial halted early after just 3 patients

NCT ID NCT06509906

Terminated Disease control Sponsor: EMD Serono Research & Development Institute, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tested a new drug called M9466 combined with standard chemotherapy in people with advanced solid tumors or colorectal cancer who had no other treatment options. Only 3 people took part before the study was stopped. The main goal was to check safety and find the right dose, but no conclusions can be drawn from such a small, terminated study.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: M9466 (PARP1 inhibitor) combined with irinotecan, folinic acid, fluorouracil, and bevacizumab
What this could lead to: If successful, this could point toward a new combination treatment option for advanced solid tumors and colorectal cancer.
What could go wrong: This was a very early Phase 1 trial with only 3 participants and has been terminated, so results are extremely limited. The combination may cause significant side effects and may not work in larger groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMOR

Contacts and locations

Locations

Cancer Research SA

Elizabeth Vale, Australia
Carolina BioOncology Institute, LLC - Cancer Therapy and Research Center

Pennington, New Jersey, 08534, United States
NEXT Barcelona - NEXT Barcelona

Barcelona, Spain
NEXT Madrid - Hospital Universitario Quironsalud Madrid

Pozuelo de Alarcón, Spain
National Cancer Center Hospital

Chūōku, Japan
Peter MacCallum Cancer Centre - Use the one with Account 2 VCCC

Parkville, Australia
Samsung Medical Center

Seoul, South Korea
Sarah Cannon Research Institute at Health One

Denver, Colorado, 80218, United States
Seoul National University Hospital

Seoul, South Korea
St George Private Hospital

Kogarah, Australia
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030-4009, United States
Vanderbilt University - 150912667

Nashville, Tennessee, 37232, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.